论文部分内容阅读
Hepatitis C virus(HCV) is an important etiologic agent of hepatitis and a major cause of chronic liver infection that often leads to cirrhosis, fibrosis and hepatocellular carcinoma. Although, HCV is a hepatotropic virus, there is strong evidence that HCV could replicate extrahepatic in the gastrointestinal tissue which could serve as a reservoir for HCV. The outcome of HCV infection depends mainly on the host innate and adaptive immune responses. Innate immunity against HCV includes mainly nuclear factor cells and activation of IFN-related genes. There is an immunologic link between the gut and the liver through a population of T-cells that are capable of homing to both the liver and gut via the portal circulation. However, little is known on the role of Gut immune response in HCV. In this review we discussed the immune regulation of Gut immune cells and its association with HCV pathogenesis, various outcomes of anti-HCV therapy, viral persistence and degree of liver inflammation. Additionally, we investigated the relationship between Gut immune responses to HCV and IL28Bgenotypes, which were identified as a strong predictor for HCV pathogenesis and treatment outcome after acute infection.
Hepatitis C virus (HCV) is an important etiologic agent of hepatitis and a major cause of chronic liver infection that often leads to cirrhosis, fibrosis and hepatocellular carcinoma. Although HCV is a hepatotropic virus, there is strong evidence that that HCV could replicate extrahepatic in the gastrointestinal tissue which could serve as a reservoir for HCV. There is an immunologic link between the gut and the liver through a population of T-cells that are capable of homing to both liver and gut via the portal circulation. However, little is known on the role of Gut immune response in HCV. immune regulation of Gut immune cells and its association with HCV pathogenesis, various outcomes of anti-HCV therapy, viral persistence and degree of liver inflammation. Add itionally, we investigated the relationship between Gut immune responses to HCV and IL28 B genotypes, which were identified as a strong predictor for HCV pathogenesis and treatment outcome after acute infection.